An Exploration of Current and Emerging Therapies for mCRPC
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
Inflammatory Breast Cancer: A New Scoring System Proposed
Filipa Lynce, MD
PeerSABCS 2023: A Look into New Research for Inflammatory Breast Cancer
Filipa Lynce, MD
PeerA Look at What’s New in Invasive Lobular Carcinoma
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Examining the Economic Impacts of Biosimilars in Oncology